Presented by:

	Michael K. Gibson, MD, PhD Vanderbilt-Ingram Cancer Center
	Rajiv Agarwal, MD, MSCI Vanderbilt-Ingram Cancer Center

Learning Objectives:
Following this activity, participants should be able to:

• Discuss the updated NCCN Guidelines and application of immune checkpoint inhibitors (ICIs) for clinical management of locally advanced/metastatic esophagogastric/esophagogastric junction (EGJ) cancer.
• Evaluate available clinical evidence for biomarker-directed treatment with ICIs for frontline treatment of locally advanced/metastatic esophagogastric/EGJ cancer, especially in patients with microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) tumors.
• Integrate nutritional support for patients with locally advanced/ metastatic esophagogastric/EGJ cancer.

Fee Information:
There is no fee to attend this activity.

Accreditation:
CE credit for this activity is available for the oncology care team including physicians, nurses, pharmacists, PAs, and case managers. View full accreditation information here.

Upcoming Tumor Board Webinars:

• Thursday, November 14 | Head and Neck Cancers
• Friday, November 15 | Bladder Cancer
   

Recorded Presentations: 
Access recorded presentations from this series here.

Supporters:
This activity is supported by educational grants from AstraZeneca; Coherus BioSciences; Eisai Inc.; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Novartis; and Sanofi. This activity is supported by independent educational grants from Daiichi Sankyo and Merck & Co., Inc., Rahway, NJ, USA. This is activity is supported by independent medical education grants from AbbVie and GSK.